论文部分内容阅读
目的探讨尖锐湿疣患者治疗前后血清内脂素(visfatin)和高迁移率蛋白-1(HMGB1)水平的变化及意义。方法采用酶联免疫(ELISA)法检测血清内脂素和HMGB1含量;分别对62例尖锐湿疣患者进行了血清内脂素和HMGB1检测,并与35名正常健康人作比较。结果在治疗前尖锐湿疣患者内脂素和HMGB1水平均非常显著地高于正常人组(P<0.01)。经3个月治疗后血清内脂素和HMGB1水平与正常人组比较无显著性差异(P>0.05)。患者组治疗前后血清内脂素和HMGB1水平也有显著性差异(P<0.01)。尖锐湿疣患者患者HMGB1浓度与内脂素浓度呈正相关(r=0.71,P<0.01)。结论检测尖锐湿疣患者血清内脂素和HMGB1水平的变化对疾病的治疗、预后观察有重要的临床价值。
Objective To investigate the changes of serum visfatin and high mobility group-1 (HMGB1) levels in patients with condyloma acuminatum before and after treatment. Methods Serum visfatin and HMGB1 levels were detected by ELISA. Serum visfatin and HMGB1 were detected in 62 patients with condyloma acuminatum and compared with 35 healthy controls. Results The levels of visfatin and HMGB1 in patients with condyloma acuminatum were significantly higher than those in normal controls before treatment (P <0.01). After 3 months of treatment, the levels of serum visfatin and HMGB1 were not significantly different from those in normal people (P> 0.05). Serum visfatin and HMGB1 levels in patients before and after treatment were also significantly different (P <0.01). Patients with condyloma acuminatum patients with HMGB1 concentration and visfatin concentration was positively correlated (r = 0.71, P <0.01). Conclusion Detecting the changes of serum visfatin and HMGB1 levels in patients with condyloma acuminatum has important clinical value in the treatment of disease and prognosis.